NASDAQ:YMAB Y-mAbs Therapeutics (YMAB) Stock Price, News & Analysis → Secret Bull Market Starts in This Unusual Sector (From Altimetry) (Ad) Free YMAB Stock Alerts $15.13 +0.13 (+0.87%) (As of 04/19/2024 ET) Add Compare Share Share Today's Range$14.71▼$15.4150-Day Range$13.76▼$18.6952-Week Range$4.60▼$20.90Volume467,186 shsAverage Volume311,360 shsMarket Capitalization$662.39 millionP/E RatioN/ADividend YieldN/APrice Target$16.57 Stock AnalysisStock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestSocial MediaStock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestSocial Media Get Y-mAbs Therapeutics alerts: Email Address Y-mAbs Therapeutics MarketRank™ Stock AnalysisAnalyst RatingHold2.33 Rating ScoreUpside/Downside9.5% Upside$16.57 Price TargetShort InterestBearish6.77% of Float Sold ShortDividend StrengthN/ASustainabilityN/ANews Sentiment-0.01Based on 3 Articles This WeekInsider TradingSelling Shares$28,283 Sold Last QuarterProj. Earnings GrowthGrowingFrom ($0.43) to ($0.29) Per ShareSee Full Details Hide Full Details Overall MarketRank™New Rank-Based ScoringMarketRank™ is calculated by averaging available category scores (with extra weight given to analysis and valuation), then ranking the company's weighted average against that of other companies.0.33 out of 5 starsMedical Sector835th out of 911 stocksPharmaceutical Preparations Industry375th out of 410 stocks 1.2 Analyst's Opinion Consensus RatingY-mAbs Therapeutics has received a consensus rating of Hold. The company's average rating score is 2.33, and is based on 4 buy ratings, no hold ratings, and 2 sell ratings.Amount of Analyst CoverageY-mAbs Therapeutics has only been the subject of 4 research reports in the past 90 days. Previous Next 1.0 Short Interest Percentage of Shares Shorted6.77% of the float of Y-mAbs Therapeutics has been sold short.Short Interest Ratio / Days to CoverY-mAbs Therapeutics has a short interest ratio ("days to cover") of 5.3.Change versus previous monthShort interest in Y-mAbs Therapeutics has recently increased by 6.67%, indicating that investor sentiment is decreasing significantly. Previous Next 0.0 Dividend Strength Dividend YieldY-mAbs Therapeutics does not currently pay a dividend.Dividend GrowthY-mAbs Therapeutics does not have a long track record of dividend growth. Previous Next N/A Sustainability and ESG Overall ESG (Environmental, Social, and Governance) ScoreThere is no current Upright™ data available for YMAB. Previous Next 1.1 News and Social Media Coverage News SentimentY-mAbs Therapeutics has a news sentiment score of -0.01. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a lower news sentiment than the 0.52 average news sentiment score of Medical companies.News Coverage This WeekMarketBeat has tracked 3 news articles for Y-mAbs Therapeutics this week, compared to 2 articles on an average week.Search InterestOnly 3 people have searched for YMAB on MarketBeat in the last 30 days. This is a decrease of -50% compared to the previous 30 days.MarketBeat FollowsOnly 5 people have added Y-mAbs Therapeutics to their MarketBeat watchlist in the last 30 days. This is a decrease of -55% compared to the previous 30 days. Previous Next 4.2 Company Ownership Insider Buying vs. Insider SellingIn the past three months, Y-mAbs Therapeutics insiders have sold more of their company's stock than they have bought. Specifically, they have bought $0.00 in company stock and sold $28,283.00 in company stock.Percentage Held by Insiders21.50% of the stock of Y-mAbs Therapeutics is held by insiders. A high percentage of insider ownership can be a sign of company health.Percentage Held by Institutions70.85% of the stock of Y-mAbs Therapeutics is held by institutions. High institutional ownership can be a signal of strong market trust in this company. Previous Next 0.6 Earnings and Valuation Earnings GrowthEarnings for Y-mAbs Therapeutics are expected to grow in the coming year, from ($0.43) to ($0.29) per share.Price to Earnings Ratio vs. the MarketThe P/E ratio of Y-mAbs Therapeutics is -30.88, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Earnings Ratio vs. SectorThe P/E ratio of Y-mAbs Therapeutics is -30.88, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Book Value per Share RatioY-mAbs Therapeutics has a P/B Ratio of 6.52. P/B Ratios above 3 indicate that a company could be overvalued with respect to its assets and liabilities. Previous Next See Top Rated MarketRank™ Stocks Here Ad AltimetrySecret Bull Market Starts in This Unusual Sector"We're only at the very beginning of a new wave that could deliver 500%-plus gains in the years to come." In fact, 50 small companies related to this sector have already soared 100% or more in a recent 90-day stretch. Click for my No. 1 investment, all free of charge, click here. About Y-mAbs Therapeutics Stock (NASDAQ:YMAB)Y-mAbs Therapeutics, Inc., a commercial-stage biopharmaceutical company, focuses on the development and commercialization of antibody based therapeutic products for the treatment of cancer in the United States and internationally. It offers DANYELZA, a monoclonal antibody in combination with granulocyte-macrophage colony-stimulating factor for the treatment of pediatric patients with relapsed or refractory high-risk neuroblastoma in the bone or bone marrow. The company is also developing DANYELZA for the treatment of patients with second-line relapsed osteosarcoma and is in Phase II clinical study; GD2-SADA, which is in Phase I clinical trial for the treatment of GD2 positive solid tumor; and Omburtamab, a murine monoclonal antibody for the treatment of central nervous system/leptomeningeal metastases from neuroblastoma, as well as SADA PRIT technology platform. In addition, it is engages in the developing of CD38-SADA and GD2-GD3 Vaccine. The company has a license agreement with Memorial Sloan Kettering Cancer Center and Massachusetts Institute of Technology to develop and commercialize licensed products. Y-mAbs Therapeutics, Inc. was incorporated in 2015 and is headquartered in New York, New York.Read More YMAB Stock Price History View Price History Chart DataSkip Price History Chart 30 days | 90 days | 365 days | Advanced Chart YMAB Stock News HeadlinesApril 18, 2024 | finance.yahoo.comY-mAbs Therapeutics (NASDAQ:YMAB) rises 9.6% this week, taking one-year gains to 161%April 14, 2024 | americanbankingnews.comY-mAbs Therapeutics (NASDAQ:YMAB) & Dyne Therapeutics (NASDAQ:DYN) Critical ReviewApril 20, 2024 | Gold Safe Exchange (Ad)The “Perfect Storm” for GoldGold has already reached all-time highs, and experts believe it's not slowing down any time soon. In fact, some analysts predict a $7,000 price tag by 2025.April 13, 2024 | americanbankingnews.comY-mAbs Therapeutics (NASDAQ:YMAB) Stock Price Up 4%April 10, 2024 | americanbankingnews.comY-mAbs Therapeutics, Inc. (NASDAQ:YMAB) Receives Average Rating of "Hold" from BrokeragesMarch 15, 2024 | marketwatch.comY-mAbs Therapeutics Finance Chief Bo Kruse ResignsMarch 14, 2024 | finanznachrichten.deY-mAbs Therapeutics, Inc.: Y-mAbs Therapeutics Announces Resignation of Chief Financial OfficerMarch 14, 2024 | markets.businessinsider.comY-mAbs Therapeutics CFO Bo Kruse To RetireApril 20, 2024 | Gold Safe Exchange (Ad)The “Perfect Storm” for GoldGold has already reached all-time highs, and experts believe it's not slowing down any time soon. In fact, some analysts predict a $7,000 price tag by 2025.March 14, 2024 | globenewswire.comY-mAbs Therapeutics Announces Resignation of Chief Financial OfficerMarch 6, 2024 | markets.businessinsider.comCracking The Code: Understanding Analyst Reviews For Y-mAbs TherapeuticsMarch 4, 2024 | finance.yahoo.comY-mAbs Therapeutics, Inc. (NASDAQ:YMAB) Q4 2023 Earnings Call TranscriptMarch 4, 2024 | globenewswire.comY-mAbs Appoints Oncology Executive Mary Tagliaferri, M.D. to its Board of DirectorsMarch 4, 2024 | globenewswire.comY-mAbs Appoints Oncology Executive Mary Tagliaferri, M.D. to its Board of DirectorsMarch 3, 2024 | finance.yahoo.comY-mAbs Therapeutics Full Year 2023 Earnings: Beats ExpectationsMarch 2, 2024 | finance.yahoo.comQ4 2023 Y-mAbs Therapeutics Inc Earnings CallMarch 1, 2024 | finanznachrichten.deY-mAbs Therapeutics, Inc.: Y-mAbs Reports Fourth Quarter and Full Year 2023 Financial Results and Recent Corporate DevelopmentsFebruary 29, 2024 | msn.comY-mAbs up 17% after hours on strong 2024 guidance, quarterly beatsFebruary 29, 2024 | finance.yahoo.comY-mAbs Therapeutics Inc (YMAB) Reports Strong Revenue Growth in Q4 and Full Year 2023February 29, 2024 | globenewswire.comY-mAbs Reports Fourth Quarter and Full Year 2023 Financial Results and Recent Corporate DevelopmentsFebruary 28, 2024 | msn.comY-mAbs Therapeutics FY 2023 Earnings PreviewFebruary 28, 2024 | markets.businessinsider.comHere's what Wall Street expects from Y-mAbs Therapeutics's earningsFebruary 21, 2024 | wsj.comY-mAbs Therapeutics Inc.February 17, 2024 | finance.yahoo.comYMAB Mar 2024 20.000 callFebruary 17, 2024 | finance.yahoo.comYMAB Mar 2024 10.000 callFebruary 16, 2024 | finance.yahoo.comCRISPR Therapeutics AG (CRSP) Moves 6.9% Higher: Will This Strength Last?February 16, 2024 | finance.yahoo.comY-mAbs to Announce Fourth Quarter and Full Year 2023 Financial and Operating Results on February 29, 2024See More Headlines Receive YMAB Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Y-mAbs Therapeutics and its competitors with MarketBeat's FREE daily newsletter. Email Address Company Calendar Last Earnings2/29/2024Today4/19/2024Next Earnings (Estimated)5/13/2024Fiscal Year End12/31/2024Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeNASDAQ SectorMedical Industry Pharmaceutical preparations Sub-IndustryN/A Current SymbolNASDAQ:YMAB CUSIPN/A CIK1722964 Webwww.ymabs.com Phone(646) 885-8505FaxN/AEmployees100Year FoundedN/APrice Target and Rating Average Stock Price Target$16.57 High Stock Price Target$26.00 Low Stock Price Target$5.00 Potential Upside/Downside+9.5%Consensus RatingHold Rating Score (0-4)2.33 Research Coverage6 Analysts Profitability EPS (Most Recent Fiscal Year)($0.49) Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income$-21,430,000.00 Net Margins-25.26% Pretax Margin-24.60% Return on Equity-20.72% Return on Assets-16.28% Debt Debt-to-Equity RatioN/A Current Ratio5.52 Quick Ratio5.27 Sales & Book Value Annual Sales$84.82 million Price / Sales7.81 Cash FlowN/A Price / Cash FlowN/A Book Value$2.32 per share Price / Book6.52Miscellaneous Outstanding Shares43,780,000Free Float34,365,000Market Cap$662.39 million OptionableOptionable Beta0.74 Metaverse Stocks And Why You Can't Ignore ThemThinking about investing in Meta, Roblox, or Unity? Click the link to learn what streetwise investors need to know about the metaverse and public markets before making an investment.Get This Free Report Key ExecutivesMr. Thomas Gad (Age 53)Founder, Chief Business Officer & Vice Chairman Comp: $1.05MMr. Bo Kruse (Age 51)Executive VP, Secretary, Treasurer & CFO Comp: $685.02kMs. Susan Smith (Age 53)Senior VP & Chief Commercial Officer Comp: $710kMr. Michael Rossi (Age 53)CEO, President & Director Mr. Joris Wiel Jan Wilms (Age 50)Senior VP & COO Dr. Torben Lund-Hansen M.Sc. (Age 73)Ph.D., Senior VP & CTO Dr. Steen Lisby M.D. (Age 60)M.Sc., Senior VP & Chief Scientific Officer Comp: $393.99kMs. Courtney DuganVice President of Investor RelationsDr. Vignesh Rajah M.B.A. (Age 59)MBBS, Senior VP & Chief Medical Officer Comp: $406.27kMore ExecutivesKey CompetitorsBicycle TherapeuticsNASDAQ:BCYCAerovate TherapeuticsNASDAQ:AVTELongboard PharmaceuticalsNASDAQ:LBPHPharming GroupNASDAQ:PHARPureTech HealthNASDAQ:PRTCView All CompetitorsInsiders & InstitutionsLos Angeles Capital Management LLCSold 228,979 shares on 4/5/2024Ownership: 0.291%Vanguard Group Inc.Bought 12,330 shares on 3/11/2024Ownership: 5.126%Vignesh RajahSold 1,711 sharesTotal: $28,282.83 ($16.53/share)Goldman Sachs Group Inc.Bought 8,604 shares on 3/1/2024Ownership: 0.912%Price T Rowe Associates Inc. MDBought 1,219 shares on 2/16/2024Ownership: 0.045%View All Insider TransactionsView All Institutional Transactions YMAB Stock Analysis - Frequently Asked Questions Should I buy or sell Y-mAbs Therapeutics stock right now? 6 Wall Street equities research analysts have issued "buy," "hold," and "sell" ratings for Y-mAbs Therapeutics in the last year. There are currently 2 sell ratings and 4 buy ratings for the stock. The consensus among Wall Street equities research analysts is that investors should "hold" YMAB shares. A hold rating indicates that analysts believe investors should maintain any existing positions they have in YMAB, but not buy additional shares or sell existing shares. View YMAB analyst ratings or view top-rated stocks. What is Y-mAbs Therapeutics' stock price target for 2024? 6 Wall Street research analysts have issued 1 year price targets for Y-mAbs Therapeutics' shares. Their YMAB share price targets range from $5.00 to $26.00. On average, they anticipate the company's share price to reach $16.57 in the next year. This suggests a possible upside of 9.5% from the stock's current price. View analysts price targets for YMAB or view top-rated stocks among Wall Street analysts. How have YMAB shares performed in 2024? Y-mAbs Therapeutics' stock was trading at $6.82 at the start of the year. Since then, YMAB shares have increased by 121.8% and is now trading at $15.13. View the best growth stocks for 2024 here. When is Y-mAbs Therapeutics' next earnings date? The company is scheduled to release its next quarterly earnings announcement on Monday, May 13th 2024. View our YMAB earnings forecast. How were Y-mAbs Therapeutics' earnings last quarter? Y-mAbs Therapeutics, Inc. (NASDAQ:YMAB) released its quarterly earnings results on Thursday, February, 29th. The company reported ($0.02) earnings per share for the quarter, topping the consensus estimate of ($0.19) by $0.17. The firm had revenue of $23.36 million for the quarter, compared to the consensus estimate of $21.72 million. Y-mAbs Therapeutics had a negative trailing twelve-month return on equity of 20.72% and a negative net margin of 25.26%. What ETFs hold Y-mAbs Therapeutics' stock? ETFs with the largest weight of Y-mAbs Therapeutics (NASDAQ:YMAB) stock in their portfolio include Range Cancer Therapeutics ETF (CNCR).Loncar China Biopharma ETF (CHNA). What guidance has Y-mAbs Therapeutics issued on next quarter's earnings? Y-mAbs Therapeutics updated its FY 2024 earnings guidance on Thursday, February, 29th. The company provided earnings per share (EPS) guidance of for the period. The company issued revenue guidance of $95.0 million-$100.0 million, compared to the consensus revenue estimate of $96.3 million. What other stocks do shareholders of Y-mAbs Therapeutics own? Based on aggregate information from My MarketBeat watchlists, some companies that other Y-mAbs Therapeutics investors own include Bank of Hawaii (BOH), InterDigital (IDCC), STAG Industrial (STAG), Corbus Pharmaceuticals (CRBP), CTI BioPharma (CTIC), Nabriva Therapeutics (NBRV), Occidental Petroleum (OXY), VBI Vaccines (VBIV), Vaxart (VXRT) and Amarin (AMRN). When did Y-mAbs Therapeutics IPO? Y-mAbs Therapeutics (YMAB) raised $80 million in an initial public offering (IPO) on Friday, September 21st 2018. The company issued 5,300,000 shares at a price of $14.00-$16.00 per share. BofA Merrill Lynch, Cowen and Canaccord Genuity served as the underwriters for the IPO and BTIG was co-manager. Who are Y-mAbs Therapeutics' major shareholders? Y-mAbs Therapeutics' stock is owned by many different institutional and retail investors. Top institutional shareholders include Los Angeles Capital Management LLC (0.29%). Insiders that own company stock include Biotech Aps Wg, Bo Kruse, Johan Wedell-Wedellsborg, Thomas Gad and Vignesh Rajah. View institutional ownership trends. How do I buy shares of Y-mAbs Therapeutics? Shares of YMAB stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. Compare Top Brokerages Here. This page (NASDAQ:YMAB) was last updated on 4/20/2024 by MarketBeat.com Staff From Our PartnersThe “Perfect Storm” for GoldGold Safe ExchangeBiden’s $374B Giveaway Into This SectorDTISHOCKING Crypto Leak…Crypto 101 MediaYour Money is Not SafeAmerican AlternativeThe #1 Crypto for 2024InvestorPlaceDid You Get Your Free Bitcoin Yet?Crypto Swap ProfitsUrgent alert: open this for a huge profit potentialTimothy SykesTiny Biotech Stock Wins $75 Billion PatentBehind the Markets Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Y-mAbs Therapeutics, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Get 30 Days of MarketBeat All Access Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools: Best-in-Class Portfolio Monitoring View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio. Stock Ideas and Recommendations Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report. Advanced Stock Screeners and Research Tools Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis. Start Your 30-Day Free Trial Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.